{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:36:38Z","timestamp":1760369798833,"version":"build-2065373602"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jaad.2021.12.067","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T03:20:53Z","timestamp":1645500053000},"page":"1-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sj\u00f6gren syndrome"],"prefix":"10.1016","volume":"87","author":[{"given":"Lauren","family":"Skudalski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Shahriari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sueheidi","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorin","family":"Bibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Kodomudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2019.07.010","article-title":"Management of cutaneous manifestations of lupus erythematosus: a systematic review","volume":"50","author":"Fairley","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.067_bib2","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options part I","volume":"65","author":"Kuhn","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.067_bib3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/bjd.20597","article-title":"British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021","volume":"185","author":"O\u2019Kane","year":"2021","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.067_bib4","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/0961203314532699","article-title":"Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel","volume":"23","author":"Petri","year":"2014","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.067_bib5","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic\u00a0lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib6","first-page":"81","article-title":"Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies","volume":"93","author":"Little","year":"2020","journal-title":"Yale J Biol Med"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.067_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrneph.2015.33","article-title":"Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis","volume":"11","author":"Mohan","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jaad.2021.12.067_bib8","unstructured":"Gilead Sciences. Study of GS-5718 in participants with cutaneous lupus erythematosus (CLE). ClinicalTrials.gov identifier: NCT04809623. Updated March 22, 2021. Accessed February 2, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04809623"},{"key":"10.1016\/j.jaad.2021.12.067_bib9","unstructured":"Proof of concept study of SAR443122 in patients with cutaneous lupus erythematosus (CLEan). ClinicalTrials.gov identifier: NCT04781816. Updated February 11, 2022. Accessed March 5, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04781816"},{"key":"10.1016\/j.jaad.2021.12.067_bib10","article-title":"5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY)","volume":"6","author":"Singhal","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jaad.2021.12.067_bib11","unstructured":"A study to assess the safety and drug levels of BMS-986256 in participants with active cutaneous lupus erythematosus. ClinicalTrials.gov identifier: NCT04493541. Updated July 30, 2020. Accessed January 11, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04493541"},{"key":"10.1016\/j.jaad.2021.12.067_bib12","unstructured":"Open-label study of tofacitinib for moderate to severe skin involvement in young adults with lupus. ClinicalTrials.gov identifier: NCT03288324. Updated December 6, 2021. Accessed February 2, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03288324"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.120.000275","article-title":"Discovery of M5049: A novel selective toll-like receptor 7\/8 inhibitor for treatment of autoimmunity","volume":"376","author":"Vlach","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2021.12.067_bib14","unstructured":"Study of M5049 in CLE and SLE participants. ClinicalTrials.gov identifier: NCT04647708. Updated December 1, 2020. Accessed February 15, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04647708"},{"issue":"4 suppl 1","key":"10.1016\/j.jaad.2021.12.067_bib15","first-page":"AB141","article-title":"Treatment with BIIB059, a monoclonal antibody targeting BDCA2, improves skin lesions in subjects with systemic lupus erythematosus (SLE) and active cutaneous LE (CLE)","volume":"81","author":"Werth","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10928-020-09688-y","article-title":"A clinical population pharmacokinetic\/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus","volume":"47","author":"Hartmann","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"595","key":"10.1016\/j.jaad.2021.12.067_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type i interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2021.12.067_bib18","unstructured":"Nicotinamide treatment for lupus-associated skin lesions in lupus erythematosus. ClinicalTrials.gov identifier: NCT03260166. Updated February 2, 2021. Accessed February 15, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03260166"},{"key":"10.1016\/j.jaad.2021.12.067_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nrrheum.2013.98","article-title":"Phase III ocrelizumab trial halted by infections","volume":"9","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.jaad.2021.12.067_bib20","article-title":"Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis","volume":"72","author":"Furie","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/1744666X.2018.1450141","article-title":"Epratuzumab for the treatment of systemic lupus erythematosus","volume":"14","author":"Geh","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"suppl 10","key":"10.1016\/j.jaad.2021.12.067_bib22","article-title":"A novel biomarker identifies systemic lupus erythematous (SLE) patients who benefit from obexelimab (XmAb\u00ae5871) treatment","volume":"72","author":"Ding","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four\u2013week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2021.12.067_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/annrheumdis-2021-eular.1401","article-title":"POS0687 A randomised dose ranging, placebo-controlled, phase II study assessing the efficacy and safety of BI 655064, an antagonistic anti-CD40 antibody, in patients with lupus nephritis","volume":"80","author":"Jayne","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.12.067_bib26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/annrheumdis-2019-eular.5529","article-title":"FRI0195 Efficacy and safety of dapirolizumab pegol (DZP) in patients with moderately to severely active systemic lupus erythematosus (SLE): a randomised, placebo (PBO)-controlled study","volume":"78","author":"Furie","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0961203316670731","article-title":"Biological therapies in the treatment of cutaneous lupus erythematosus","volume":"26","author":"Presto","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2021.12.067_bib28","doi-asserted-by":"crossref","first-page":"539797","DOI":"10.3389\/fimmu.2020.539797","article-title":"A comprehensive review of biological agents for lupus: beyond single target","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"issue":"suppl5","key":"10.1016\/j.jaad.2021.12.067_bib29","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/rheumatology\/keaa403","article-title":"Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs","volume":"59","author":"Ruiz-Irastorza","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.067_bib30","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.067_bib31","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.jaad.2020.05.058","article-title":"Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients","volume":"83","author":"Salle","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/17843286.2018.1521904","article-title":"Rituximab in systemic autoimmune rheumatic diseases: indications and practical use","volume":"74","author":"Berghen","year":"2019","journal-title":"Acta Clin Belg"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ib\u00e1\u00f1ez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.067_bib35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jamadermatol.2018.3793","article-title":"Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus","volume":"154","author":"Quelhas da Costa","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.067_bib36","first-page":"622","article-title":"Epratuzumab not effective in phase III trials","volume":"12","author":"Onuora","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2021.12.067_bib37","article-title":"290 Development and first-in-human characterization of an ICOSL and BAFF bispecific inhibitor AMG 570 for SLE treatment","volume":"6","author":"Cheng","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cei.12705","volume":"183","author":"Masek-Hammerman","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2021.12.067_bib39","unstructured":"To evaluate the preliminary safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CC-11050 in subjects with discoid lupus erythematosus and subacute cutaneous lupus erythematosus. ClinicalTrials.gov identifier: NCT01300208. Updated June 23, 2020. Accessed February 15, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01300208"},{"key":"10.1016\/j.jaad.2021.12.067_bib40","first-page":"keab685","volume":"8","author":"Werth","year":"2021","journal-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomised, double-blind, placebo-controlled study"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.067_bib41","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/exd.14253","article-title":"Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: a double-blind phase Ib study","volume":"30","author":"Walker","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2021.12.067_bib42","unstructured":"A study of the safety and pharmacokinetics of CNTO 136 in patients with cutaneous lupus erythematosus and systemic lupus erythematosis. ClinicalTrials.gov identifier: NCT01702740. Updated October 8, 2012. Accessed March 5, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01702740"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib43","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.067_bib44","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.067_bib45","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti\u2013interferon-\u03b3 antibody, in patients with discoid lupus erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.067_bib46","article-title":"Drugs for discoid lupus erythematosus","volume":"5","author":"Jessop","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.067_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/BOR.0000000000000087","article-title":"Advances in understanding the role of type I interferons in systemic lupus erythematosus","volume":"26","author":"Crow","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.trsl.2014.10.005","article-title":"Targeting of type i interferon in systemic autoimmune diseases","volume":"165","author":"Crow","year":"2015","journal-title":"Transl Res"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib49","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.jaad.2021.12.067_bib50","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20132620","article-title":"Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model","volume":"211","author":"Rowland","year":"2014","journal-title":"J Exp Med"},{"issue":"13","key":"10.1016\/j.jaad.2021.12.067_bib51","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1084\/jem.20101048","article-title":"Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9","volume":"207","author":"Guiducci","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2021.12.067_bib52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/annrheumdis-2020-eular.5743","volume":"79","author":"Werth","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"10.1016\/j.jaad.2021.12.067_bib53","article-title":"Targeting plasmacytoid dendritic cells improves cutaneous lupus erythematosus skin\u00a0lesions and reduces type I interferon levels: results of a\u00a0phase 1 study of VIB7734","volume":"72","author":"Werth","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.067_bib54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib55","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamadermatol.2018.5077","article-title":"Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation","volume":"155","author":"Zimmermann","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/annrheumdis-2018-214037","article-title":"Efficacy of JAK1\/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency","volume":"78","author":"Briand","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2021.12.067_bib57","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fimmu.2020.00344","article-title":"Selective Janus kinase 1 inhibition is a promising therapeutic approach for lupus erythematosus skin lesions","volume":"11","author":"Fetter","year":"2020","journal-title":"Front Immunol"},{"issue":"10143","key":"10.1016\/j.jaad.2021.12.067_bib58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib60","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2021.12.067_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2021-eular.1471","article-title":"OP0131 Anifrolumab effects on rash and arthritis in patients with SLE and impact of interferon signal in pooled data from phase 3 trials","volume":"80","author":"Merrill","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.067_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11882-020-00906-8","article-title":"Cutaneous lupus erythematosus: progress and challenges","volume":"20","author":"Petty","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jdcr.2019.01.015","article-title":"Ustekinumab-induced subacute cutaneous lupus","volume":"5","author":"Tierney","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib65","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1111\/ijd.14773","article-title":"Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus","volume":"59","author":"Mazgaj","year":"2020","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.067_bib66","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0961203312441982","article-title":"Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus","volume":"21","author":"Winchester","year":"2012","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib67","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2340\/00015555-1467","article-title":"Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report","volume":"93","author":"Dahl","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.067_bib68","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archdermatol.2011.185","article-title":"Successful treatment of subacute lupus erythematosus with ustekinumab","volume":"147","author":"De Souza","year":"2011","journal-title":"Arch Dermatol"},{"issue":"10155","key":"10.1016\/j.jaad.2021.12.067_bib69","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib70","article-title":"Interventions for cutaneous disease in systemic lupus erythematosus","volume":"3","author":"Hannon","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13417","article-title":"Secukinumab-induced subacute cutaneous lupus erythematosus","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00105-017-4071-8","article-title":"Secukinumab-induced subacute-cutaneous lupus erythematosus","volume":"69","author":"Wehrmann","year":"2018","journal-title":"Hautarzt"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib73","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jdcr.2020.02.013","article-title":"Secukinumab-induced chronic discoid lupus erythematosus","volume":"6","author":"Chatzimichail","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.067_bib74","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.067_bib75","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib76","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4049\/jimmunol.1600583","article-title":"Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity","volume":"198","author":"Dudhgaonkar","year":"2017","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.067_bib77","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/eji.201646641","article-title":"Deficiency in IRAK4 activity attenuates manifestations of murine lupus","volume":"47","author":"Murphy","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2021.12.067_bib78","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/annrheumdis-2021-eular.2238","article-title":"POS0672 First-in-human study of GS-5718, an oral IRAK-4 inhibitor, in healthy subjects: pharmacokinetics, safety, tolerability, and assessment of effect of food and acid reducing agents on exposure","volume":"80","author":"Anderson","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib79","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2018.05.021","article-title":"Cutaneous features and diagnosis of primary Sj\u00f6gren syndrome: an update and review","volume":"79","author":"Jhorar","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.067_bib80","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clindermatol.2006.07.005","article-title":"Sj\u00f6gren\u2019s syndrome in dermatology","volume":"24","author":"Fox","year":"2006","journal-title":"Clin Dermatol"},{"issue":"17","key":"10.1016\/j.jaad.2021.12.067_bib81","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1080\/14656566.2021.1951224","article-title":"An update of targeted therapeutic options for primary Sj\u00f6gren syndrome: current status and future development","volume":"22","author":"Retamozo","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib82","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome: an open-label clinical trial and mechanistic analysis","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib83","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150749","article-title":"Rituximab effectiveness and safety for treating primary Sj\u00f6gren\u2019s syndrome (pSS): systematic review and meta-analysis","volume":"11","author":"Souza","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jaad.2021.12.067_bib86","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3389\/fmed.2020.00534","article-title":"Comparison of rituximab originator with CT-P10 biosimilar in patients with primary Sj\u00f6gren\u2019s syndrome: a retrospective analysis in a real-life setting","volume":"7","author":"Pavlych","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaad.2021.12.067_bib87","first-page":"167","article-title":"Present and novel biologic drugs in primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Fasano","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.12.067_bib88","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/BOR.0000000000000754","article-title":"Biologics in the treatment of Sj\u00f6gren\u2019s syndrome, systemic lupus erythematosus, and lupus nephritis","volume":"32","author":"Narain","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2021.12.067_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/annrheumdis-2021-eular.2170","article-title":"OP0135 Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sj\u00f6gren\u2019s syndrome: a phase 2, randomised, placebo-controlled 68-week study","volume":"80","author":"Mariette","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib90","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety\u00a0of\u00a0belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib91","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","article-title":"BLyS upregulation in Sj\u00f6gren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands","volume":"52","author":"Quartuccio","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/rheumatology\/kes235","article-title":"The B-lymphocyte stimulator connection in Sj\u00f6gren\u2019s syndrome","volume":"52","author":"Ramos-Casals","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.jaad.2021.12.067_bib93","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib94","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.12.067_bib95","article-title":"OP0045 Abatacept treatment of patients with early active primary Sj\u00f6gren\u2019s syndrome \u2013 a randomized, double-blind placebo-controlled phase","volume":"78","author":"Spijkervet","year":"2019","journal-title":"Ann Rheum Dis"},{"author":"Fisher","key":"10.1016\/j.jaad.2021.12.067_bib96"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib97","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.067_bib98","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren\u2019s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2021.12.067_bib99","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaad.2021.12.067_bib100","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-eular.4277","article-title":"FRI0174 Subcutaneous dosing of the novel anti-CD40 antibody iscalimab achieves target drug exposure and clinical efficacy in primary Sj\u00f6gren\u2019s syndrome; results of a phase IIa randomised open label two arm parallel group trial","volume":"78","author":"Fisher","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.12.067_bib101","article-title":"THU0264 A selective JAK1 inhibitor, filgotinib suppresses lymphocytic infiltration in salivary gland of non obese diabetic mice via suppression of BAFF production of salivary gland epithelial cells","volume":"75","author":"Lee","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2021.12.067_bib102","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/rheumatology\/keaa670","article-title":"Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Barrera","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib103","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK inhibitors: prospects in connective tissue diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"18","key":"10.1016\/j.jaad.2021.12.067_bib104","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jaad.2021.12.067_bib105","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/annrheumdis-2016-209330","article-title":"Tofacitinib for polyarteritis nodosa: a tailored therapy","volume":"75","author":"Rimar","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.067_bib106","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/rheumatology\/kev102","article-title":"Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis","volume":"54","author":"Ciccia","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","article-title":"Inhibition of JAK-STAT signaling by baricitinib reduces interferon-\u03b3-induced CXCL10 production in human salivary gland ductal cells","volume":"44","author":"Aota","year":"2021","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib108","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/ar3318","article-title":"Aspects of innate immunity in Sj\u00f6gren\u2019s syndrome","volume":"13","author":"Low","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.jaad.2021.12.067_bib109","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren\u2019s syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.12.067_bib111","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.4049\/jimmunol.1601142","article-title":"Blood-borne RNA correlates with disease activity and IFN-stimulated gene expression in systemic lupus erythematosus","volume":"197","author":"Doedens","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2021.12.067_bib112","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.4110\/in.2019.19.e4","article-title":"Potential implications of long noncoding RNAs in autoimmune diseases","volume":"19","author":"Hur","year":"2019","journal-title":"Immune Netw"},{"key":"10.1016\/j.jaad.2021.12.067_bib113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaut.2013.11.003","article-title":"Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sj\u00f6gren\u2019s syndrome","volume":"51","author":"Gong","year":"2014","journal-title":"J Autoimmun"},{"issue":"1 suppl","key":"10.1016\/j.jaad.2021.12.067_bib114","article-title":"BAFF induces IL-6 production by monocytes through a BAFF receptor and promotes IgG production by B cells in patients with primary Sj\u00f6gren\u2019s syndrome. (CCR3P.210)","volume":"192","author":"Yoshimoto","year":"2014","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.jaad.2021.12.067_bib115","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/art.38716","article-title":"Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sj\u00f6gren\u2019s syndrome features in lupus-prone SLE1.Yaa mice","volume":"66","author":"Maier-Moore","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2021.12.067_bib116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2021.12.067_bib117","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaad.2021.12.067_bib118","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","article-title":"PI3K signaling in cancer: beyond AKT","volume":"45","author":"Lien","year":"2017","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jaad.2021.12.067_bib119","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.jaad.2021.12.067_bib120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2021.12.067_bib121","article-title":"OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"77","author":"D\u00f6rner","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222003267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222003267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:02:59Z","timestamp":1759273379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222003267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0190962222003267"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.067","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sj\u00f6gren syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.12.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(22)00831-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}